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Adoptive transfer of polyclonal CD4CD25 regulatory T cells
(nTregs) can tolerize transplantation alloresponses and prevent
lethal acute graft-versus-host disease (GVHD). However isolation
of human CD4CD25 nTregs for adoptive immunotherapy in
sufﬁcient numbers is cumbersome and prone to contamination
with non-regulatory, alloreactive CD25 T-cells. Incubation of
ethylcarbodiimide (ECDI)-coupled antigen presenting cells (APC)
with naı¨ve T-cells and antigen has been shown to have tolerizing
potential in various experimental models.
We have therefore hypothesized that ECDI-coupled APC would
be able to tolerize alloreactive naı¨ve CD4 T-cells from HLA-
incompatible human donors, and have tested whether this would
induce an alloantigen-speciﬁc, Treg-like CD4 population
(ECDI-Tregs). We further investigated whether these cells could
be expanded ex vivo without loss of their regulatory capacity.
After 5 days of culture, ECDI-Tregs were equally potent as
freshly isolated nTregs to suppress proliferation of effector T-cells
in a mixed lymphocyte reaction with allo-APC from the original
APC donor but not with third party APC. Foxp3 mRNA levels in
ECDI-Tregs were equal to nTregs and up to 10-fold higher than
in freshly isolated CD4 cells. The effector T-cells co-cultured
with ECDI-Tregs secreted markedly reduced levels of IL-4, IL-10,
IFN- and TNF-
, similar to cultures with nTregs. Addition of
IL-2 and rapamycin and weekly re-stimulation with untreated
allo-APC led to exponential expansion of ECDI-Tregs with in-
creasing foxp3 levels and without loss of their suppressive activity
after 28 days.
These ﬁndings provide a proof of principle that ECDI-coupled
allo-APC can induce a potent, alloantigen-speciﬁc regulatory T-
cell population that can be expanded ex vivo. These inducible
Tregs suggests a novel approach to enhance the feasibility and
effectiveness of inducing tolerance by Tregs as an adoptive immu-
notherapy in transplantation.
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RITUXIMAB INFUSION TWO MONTHS AFTER TOTAL LYMPHOID IRRA-
DIATION-ANTITHYMOCYTE GLOBULIN (TLI-ATG) NONMYELOABLA-
TIVE TRANSPLANTATION MAINTAINS B-CELL DISEASE CONTROL WITH
MINIMAL GVHD
Arai, S.1, Sahaf, B.1, Jones, C.1, Zehnder, J.1, Lowsky, R.1, Strober, S.1,
Shizuru, J.1, Negrin, R.1, Johnston, L.1, Laport, G.1, Goldstein, K.1,
Brown, J.1, Elder, L.1, Tierney, K.1, Lavori, P.1, Miklos, D.1 1Stanford
University, Stanford, CA.
B cells are implicated in the pathophysiology of chronic GVHD,
as evidenced by the association of Ab production against minor
histocompatibility Ags and rituximab efﬁcacy in chronic GVHD.
We hypothesize that anti-B cell therapy starting day 56 after
nonmyeloablative TLI-ATG transplantation can diminish donor B
cell immunity and thereby reduce chronic GVHD. We chose
chronic lymphocytic leukemia (CLL) and mantle cell lymphoma
(MCL) for the ability to offset any loss of GVL with rituximab’s
direct anti-B cell tumor efﬁcacy.
Patients were conditioned with TLI (80 cGy in10 fractions,
d-11 to d-1) and ATG (1.5mg/kg/day, d-11 to d-7, total 7.5mg/
kg). PBSC infused day 0. GVHD prophylaxis was MMF and
cyclosporine. Rituximab (375 mg/m2) was infused on days 56,
63, 70, and 77.
Fourteen patients have received HCT and the 4 rituximab
infusions. Median age 58 (range 46-65). All 6 CLL patients were
ﬂudarabine-refractory and had unmutated IgVH. Median fol-
low-up 322 days. No infusional toxicities but transient leuko-
penia was noted post-rituximab. One graft failure occurred at
d136 in a patient with MCL progression. Full donor chimerism
occurred as late as 6-9 months with objective GVL. Peripheral
CD19 B cells were undetectable post-rituximab and are re-
constituting at one year. Infections post-transplant include early
CMV reactivation (5), inﬂuenza B (1), aspergillus sinusitis (2),
ecthyma gangrenosum (1), VZV (1). All infections resolved.
NRM at 100 days is 0%. All 6 CLL patients had measurable
disease with ﬁve achieving molecular remission. One CLL pa-
tient had mixed chimerism with CLL progression and received
DLI 9 months after HCT achieving complete molecular CR,
complete chimerism and no GVHD at 60 days. Four MCL
patients transplanted in CR remain in CR. Among the 4 MCL
patients transplanted in PR, one achieved CR and 3 progressed
before rituximab infusion and subsequently died. No acute
GVHD has occurred. Two patients developed chronic GVHD
that resolved with steroids.
In summary, rituximab infusion 56-77 days after TLI-ATG
HCT is well tolerated and provides safe in vivo peripheral donor B
cell depletion without detrimental effect on engraftment or infec-
tion incidence. No acute GVHD occurred and thus far low chronic
GVHD is observed. Importantly, GVL is maintained in all 6 CLL
patients.
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CDR3 SIZE SPECTRATYPE ANALYSIS OF PATIENTS WITH CHRONIC
GRAFT-VERSUS HOST DISEASE REVEALS COMPLEXITY OF THE T CELL
REPERTOIRE
Azhipa, O.Y.1, Rowley, S.D.1, Donato, M.L.1, Korngold, R.1,
Friedman, T.M.1 1The Cancer Center, Hackensack University Medical
Center, Hackensack, NJ.
Chronic graft-versus host disease (cGVHD) in patients receiv-
ing allogeneic hematopoietic stem cell transplantation (HSCT)
is a complicated syndrome with autoimmune-like features and
multiorgan manifestations. There has been a gradual increase in
the incidence of cGVHD along with the expanded use of mo-
bilized peripheral blood as a source of stem cells for transplants.
Efforts are being made to standardize the criteria for diagnosis
and staging of cGVHD, but there is little understanding of
immune perturbations associated with the disease. T cell rep-
ertoire reconstitution after allo-HSCT often takes many
months to several years and is thought to be impaired by many
factors such as conditioning regimens, diminished thymic out-
put and stem cell source. Although the perception is that
cGVHD adversely impacts the complexity and diversity of the
reconstituting repertoire, there are only a few studies that have
speciﬁcally examined the repertoire at a molecular level and the
results are inconsistent. We thus sought to assess the diversity
and complexity of the T cell repertoire of cGVHD patients by
T cell receptor V CDR3-size spectratype analysis. To this end,
a cohort of 9 patients who underwent allo-HSCT was enrolled
in the study. Eight of the 9 patients had a previous history of
acute GVHD with no evidence of infectious disease. Peripheral
blood was collected from each cGVHD patient at one time
point ranging from 4 months to 3 years, and ﬂow cytometric and
V spectratype analysis was performed. Flow cytometric anal-
ysis revealed diverse absolute numbers of CD4 and CD8 T
cells among the patients tested, which were correlated with the
post-transplant period. We determined the recipient TCR-V
complexity index within each resolvable family, which repre-
sented the percentage of the number of peaks found for each
V, relative to that found in the average corresponding V
family of 10 healthy donors. The results indicated that 41-88%
(Avg.70; Median 72%) of the resolved V families in all 9
patients were fully complex, with the lower ranges correspond-
ing to those patients sampled early post-HSCT. V 2, 4, 6, and
12 families revealed the best recovery in all patients. In addition,
all 9 patients exhibited skewing in many TCR V families,
suggesting heterogeneous T cell responses. Despite the pres-
ence of skewed T cell responses in all patients, the overall
repertoire remains complex.
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